Do NASH therapies improve dyslipidemia and reduce cardiovascular disease risk in patients with NAFLD?
Highlights the mechanistic link between NAFLD-associated lipid dysregulation and cardiovascular disease, noting that emerging NASH therapies may also improve dyslipidemia.
Alterations in hepatic lipid and lipoprotein metabolism are major contributing factors to the increased CVD risk in NAFLD patients, and many promising NASH therapies in development also improve dyslipidemia in clinical trials.
Deprince et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: